Prior to joining the BrightEdge Fund, Michael was an Associate Principal in the Life Sciences practice at Charles River Associates. While at CRA, Michael led engagements in asset/portfolio strategy, mergers and acquisitions, pipeline optimization, BD/investment strategy, and pricing & market access (primarily in oncology, rare disease, and immunology). Prior to his role at CRA, he co-founded SynActive Biosciences, which focused on stem cell-derived neuron technologies. Previously, he was a Program Manager in the Biosciences Division at the Department of Defense where he researched emerging pathogens and bio-terrorism threat agents. He has written numerous publications on genomics, immunology, infectious disease, and competitive dynamics in the biopharma marketplace, and has presented his research at leading academic conferences. He is conversant in both German and Spanish.
Michael attended The University of Wisconsin-Madison where he recieved a B.S. in Bacteriology and his PhD in Genetics. Additionally, Michael received his MBA from The University of Chicago Booth School of Business.